Shire PLC (NASDAQ:SHPG) to Release Earnings on Thursday
Shire PLC (NASDAQ:SHPG) will post its quarterly earnings results before the market opens on Thursday, August 3rd. Analysts expect Shire PLC to post earnings of $3.52 per share for the quarter. Shire PLC has set its FY17 guidance at $14.60-15.20 EPS.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $0.41. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business had revenue of $3.57 billion during the quarter. During the same quarter last year, the business earned $2.12 earnings per share. The business’s quarterly revenue was up 109.0% on a year-over-year basis. On average, analysts expect Shire PLC to post $14.8 EPS for the current fiscal year and $16.33 EPS for the next fiscal year.
Shares of Shire PLC (SHPG) traded down 0.29% during mid-day trading on Thursday, reaching $169.30. 1,335,612 shares of the company’s stock traded hands. Shire PLC has a 12-month low of $158.54 and a 12-month high of $209.22.
Several equities research analysts have issued reports on SHPG shares. Royal Bank Of Canada set a $221.00 price objective on shares of Shire PLC and gave the company a “buy” rating in a research report on Thursday, May 18th. Jefferies Group LLC set a $239.00 price objective on shares of Shire PLC and gave the company a “buy” rating in a research report on Thursday, April 20th. Stifel Nicolaus lowered their price objective on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Finally, ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Shire PLC presently has a consensus rating of “Buy” and a consensus target price of $223.64.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.